Life Sciences Strategies for Anti-Corruption & FCPA Compliance 23-24 June Washington, DC

Advertisement

The National Law Review is  a proud media sponsor of the upcoming Life Sciences Strategies for Anti-Corruption & FCPA Compliance – which addresses  the Unique Challenges and Risk Areas Tied to FCPA and Corruption Faced by the Pharmaceuticals, Medical Device and Biotechnology Companies  

Pharmaceutical and medical device companies operating overseas are particularly vulnerable to FCPA violations because of the nature of public health systems in many foreign countries where health care systems are owned and operated by the government. Given the fact that employees are in constant contact with the health care providers at different touch points within the organization, there is a need to ensure all interactions are monitored and effective policies are in place to curb any potential violations.

Advertisement

Gain insights on how to deal with issues stemming from gifts and entertainment of government officials to develop effective training programs and best practices in operating in emerging countries as well as dealing with 3rd parties.

With a one-track focus, the Life Sciences Strategies for Anti-Corruption & FCPA Compliance Conference is a highly intensive, content-driven event that includes case studies, presentations and panel discussions over two full days. This conference targets industry leaders from the pharmaceutical, medical device and biotechnology and clinical research organizations in order to provide an intimate atmosphere for both the delegates and speakers.

Advertisement

key conference topics include:

Advertisement
  • Analyze the key provisions of the UK Bribery Bill and the impact on life sciences industries by Abbott Laboratories
  • Identify practical strategies to develop effective global anti-corruption compliance program from CareFusion
  • Assess the challenges of conducting and implementing effective global traning programs by Medtronic, Inc.
  • Advertisement
  • Develop robust internal controls for 3rd party due-diligence by Talecris Biotherapeutics, Inc.
  • Address FCPA and corruption risk stemming from sales and marketing activities and interaction from Covidien
  •  

    key conference features include:

    Advertisement
  • Expert Case Studies and Presentations by Industry Leading FCPA & Anti-Corruption Professionals
  •  

  • Illuminating Roundtable Discussions Led by St. Jude Medical (June 23rd) and Johnson & Johnson (June 24th)
  • Advertisement
  • Earn up to 16 hours of CLE Credits
  •  

    for more details and to register:


    Published by

    National Law Forum

    A group of in-house attorneys developed the National Law Review on-line edition to create an easy to use resource to capture legal trends and news as they first start to emerge. We were looking for a better way to organize, vet and easily retrieve all the updates that were being sent to us on a daily basis.In the process, we’ve become one of the highest volume business law websites in the U.S. Today, the National Law Review’s seasoned editors screen and classify breaking news and analysis authored by recognized legal professionals and our own journalists. There is no log in to access the database and new articles are added hourly. The National Law Review revolutionized legal publication in 1888 and this cutting-edge tradition continues today.